中国—东盟区域医药集采平台交易金额突破1000万元

Core Insights - The China-ASEAN Regional Pharmaceutical Procurement Platform has successfully surpassed a transaction amount of 10 million yuan, marking a significant milestone in facilitating cross-border pharmaceutical trade between China and ASEAN countries [1][2] - The platform aims to optimize regional pharmaceutical resource allocation and enhance the efficiency of medical supply chains through digital technology [1] Group 1: Platform Overview - The China-ASEAN Regional Pharmaceutical Procurement Platform is the first cross-border pharmaceutical procurement platform targeting ASEAN countries, officially operational since January 2025 [1] - The platform is based in the Fangchenggang International Medical Open Experimental Zone and provides standardized services for pharmaceutical supply and demand matching between China and ASEAN [1] Group 2: Achievements and Impact - As of now, the platform has attracted 224 leading domestic pharmaceutical companies, showcasing 1,020 types of drugs and 2,418 categories of medical consumables and equipment [2] - The platform has received procurement demands for over 170 types of pharmaceutical consumables from 19 foreign buyers, including countries like Vietnam, Thailand, and Russia, highlighting its role as a new window for cross-border pharmaceutical cooperation [2] Group 3: Efficiency and Future Prospects - The platform has significantly reduced the time required for companies to identify partners and assess product quality, enhancing responsiveness to market demands from months to weeks or even days [2] - Continued development and operation of the platform are expected to greatly improve healthcare standards in the ASEAN region [2]